Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

The IBD category overall is becoming increasingly crowded, however, with other rivals including Johnson & Johnson’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) and Takeda Pharma’s α4β7 ...

Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

Risankizumab versus ustekinumab for Crohn’s disease: a phase IIIb study Eleni Kotsiliti Research Highlights 05 Aug 2024 Nature Reviews Gastroenterology & Hepatology ...

If you have moderate to severe psoriasis, injectable medications may be a suitable option for you. Learn about the benefits and side effects of injections for psoriasis.

Centene's Guidance Withdrawal Spooks Sector, Oscar Health Stock Falls Trump-Administration's Health Agency Overstepped Authority, Reorganization Unlawful: Court Obama Warns 16 Million Americans ...

Giuliana Grossi is an editor for The American Journal of Managed Care®, overseeing the publication's Center on Health Equity & Access. Her work focuses on disparities and systemic inequities in ...

3 Results A total of six patients, five of which were male, were initiated on ustekinumab between November 2019 and June 2022 at a median age of 15.5 years (range 11–17). The median fecal calprotectin ...